Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology

por Garnett, Sally Anne, Martin, Miguel, Jerusalem, Guy, Petruzelka, Lubos, Torres, Roberto, Bondarenko, Igor N., Khasanov, Rustem, Verhoeven, Didier, Pedrini, José L., Smirnova, Iva, Lichinitser, Mikhail R., Pendergrass, Kelly, Lindemann, Justin P. O., Di Leo, Angelo
Publicado 2013

PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer

por Martín, Miguel, Prat, Aleix, Rodríguez-Lescure, Álvaro, Caballero, Rosalía, Ebbert, Mark T. W., Munárriz, Blanca, Ruiz-Borrego, Manuel, Bastien, Roy R. L., Crespo, Carmen, Davis, Carole, Rodríguez, César A., López-Vega, José M., Furió, Vicente, García, Ana M., Casas, Maribel, Ellis, Matthew J., Berry, Donald A., Pitcher, Brandelyn N., Harris, Lyndsay, Ruiz, Amparo, Winer, Eric, Hudis, Clifford, Stijleman, Inge J., Tuck, David P., Carrasco, Eva, Perou, Charles M., Bernard, Philip S.
Publicado 2013

nab-Paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis

por O’Shaughnessy, Joyce, Gradishar, William J., Bhar, Paul, Iglesias, Jose
Publicado 2013

A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer

por Modi, Shanu, Saura, Cristina, Henderson, Charles, Lin, Nancy U., Mahtani, Reshma, Goddard, Jill, Rodenas, Eduardo, Hudis, Clifford, O’Shaughnessy, Joyce, Baselga, Jose
Publicado 2013

A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced...

por Iwata, Hiroji, Masuda, Norikazu, Ohno, Shinji, Rai, Yoshiaki, Sato, Yasuyuki, Ohsumi, Shozo, Hashigaki, Satoshi, Nishizawa, Yoshinori, Hiraoka, Masahiro, Morimoto, Tadaoki, Sasano, Hironobu, Saeki, Toshiaki, Noguchi, Shinzaburo
Publicado 2013

A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer

por Rugo, Hope S., Campone, Mario, Amadori, Dino, Aldrighetti, Daniela, Conte, PierFranco, Wardley, Andrew, Villanueva, Cristian, Melisko, Michelle, McHenry, M. Brent, Liu, David, Lee, Francis, Pivot, Xavier
Publicado 2013

A Randomized Trial of Balloon Kyphoplasty and Nonsurgical Management for Treating Acute Vertebral Compression Fractures: Vertebral Body Kyphosis Correction and Surgical Parameters

por Van Meirhaeghe, Jan, Bastian, Leonard, Boonen, Steven, Ranstam, Jonas, Tillman, John B., Wardlaw, Douglas
Publicado 2013

Reducing false-positive biopsies: a pilot study to reduce benign biopsy rates for BI-RADS 4A/B assessments through testing risk stratification and new thresholds for intervention

por Flowers, Chris I., O’Donoghue, Cristina, Moore, Dan, Goss, Adeline, Kim, Danny, Kim, June-Ho, Elias, Sjoerd G., Fridland, Julia, Esserman, Laura J.
Publicado 2013

Four-year clinical update from a prospective trial of accelerated partial breast intensity-modulated radiotherapy (APBIMRT)

por Lei, Rachel Y., Leonard, Charles E., Howell, Kathryn T., Henkenberns, Phyllis L., Johnson, Timothy K., Hobart, Tracy L., Fryman, Shannon P., Kercher, Jane M., Widner, Jodi L., Kaske, Terese, Carter, Dennis L.
Publicado 2013

The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients

por Stemmer, Salomon M., Klang, Shmuel H., Ben-Baruch, Noa, Geffen, David B., Steiner, Mariana, Soussan-Gutman, Lior, Merling, Shahar, Svedman, Christer, Rizel, Shulamith, Lieberman, Nicky
Publicado 2013

Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy

por Vahdat, Linda T., Garcia, Agustin A., Vogel, Charles, Pellegrino, Christine, Lindquist, Deborah L., Iannotti, Nicholas, Gopalakrishna, Prashanth, Sparano, Joseph A.
Publicado 2013

Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study

por Campiglio, M., Bufalino, R., Sasso, M., Ferri, E., Casalini, P., Adamo, V., Fabi, A., Aiello, R., Riccardi, F., Valle, E., Scotti, V., Tabaro, G., Giuffrida, D., Tarenzi, E., Bologna, A., Mustacchi, G., Bianchi, F., Balsari, A., Ménard, S., Tagliabue, E.
Publicado 2013

Audit-based education lowers systolic blood pressure in chronic kidney disease: the Quality Improvement in CKD (QICKD) trial results

por de Lusignana, Simon, Gallagher, Hugh, Jones, Simon, Chan, Tom, van Vlymen, Jeremy, Tahir, Aumran, Thomas, Nicola, Jain, Neerja, Dmitrieva, Olga, Rafi, Imran, McGovern, Andrew, Harris, Kevin
Publicado 2013

Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment

por Lien, Ernst A., Søiland, Håvard, Lundgren, Steinar, Aas, Turid, Steen, Vidar M., Mellgren, Gunnar, Gjerde, Jennifer
Publicado 2013

Fractional flow reserve versus angiography in guiding management to optimize outcomes in non–ST-elevation myocardial infarction (FAMOUS-NSTEMI): Rationale and design of a randomized controlled clinical trial()

por Berry, Colin, Layland, Jamie, Sood, Arvind, Curzen, Nick P., Balachandran, Kanarath P., Das, Raj, Junejo, Shahid, Henderson, Robert A., Briggs, Andrew H., Ford, Ian, Oldroyd, Keith G.
Publicado 2013

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxa...

por Hurvitz, Sara A., Dalenc, Florence, Campone, Mario, O’Regan, Ruth M., Tjan-Heijnen, Vivianne C., Gligorov, Joseph, Llombart, Antonio, Jhangiani, Haresh, Mirshahidi, Hamid R., Tan-Chiu, Elizabeth, Miao, Sara, El-Hashimy, Mona, Lincy, Jeremie, Taran, Tetiana, Soria, Jean-Charles, Sahmoud, Tarek, André, Fabrice
Publicado 2013

Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)

por Miles, David, Baselga, José, Amadori, Dino, Sunpaweravong, Patrapim, Semiglazov, Vladimir, Knott, Adam, Clark, Emma, Ross, Graham, Swain, Sandra M.
Publicado 2013

Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy

por Ohno, S., Chow, L. W. C., Sato, N., Masuda, N., Sasano, H., Takahashi, F., Bando, H., Iwata, H., Morimoto, T., Kamigaki, S., Nakayama, T., Nakamura, S., Kuroi, K., Aogi, K., Kashiwaba, M., Yamashita, H., Hisamatsu, K., Ito, Y., Yamamoto, Y., Ueno, T., Fakhrejahani, E., Yoshida, N., Toi, M.
Publicado 2013

The effect of hepatic or renal impairment on the pharmacokinetics of edivoxetine, a selective norepinephrine transporter reuptake inhibitor

por Kielbasa, William, Tesfaye, Eshetu, Luffer-Atlas, Debra, Mitchell, Malcolm I., Turik, Michael A.
Publicado 2013

Effects of vercirnon on the activity of CYP3A4, CYP2C19 and CYP2C8 enzymes and BCRP and OATP1B1 transporters using probe substrates

por Haberer, Lynda J., McSherry, Iain, Cargill, Anna, McCarthy, Linda
Publicado 2013